نتائج البحث - "Bocchia, Monica"

1

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome

المؤلفون: Palandri, Francesca, Iacobucci, Ilaria, Castagnetti, Fausto, Testoni, Nicoletta, Poerio, Angela, Amabile, Marilina, Breccia, Massimo, Intermesoli, Tamara, Iuliano, Francesco, Rege Cambrin, Giovanna, Tiribelli, Mario, Miglino, Maurizio, Pane, Fabrizio, Saglio, Giuseppe, Martinelli, Giovanni, Rosti, Gianantonio, Baccarani, Michele, GIMEMA CML Working Party, Bocchia, Monica

المساهمون: Palandri F, Iacobucci I, Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, GIMEMA Working Party on CML., Francesca, Palandri, Ilaria, Iacobucci, Fausto, Castagnetti, Nicoletta, Testoni, Angela, Poerio, Marilina, Amabile, Massimo, Breccia, Tamara, Intermesoli, Francesco, Iuliano, Giovanna Rege, Cambrin, Mario, Tiribelli, Maurizio, Miglino, Pane, Fabrizio, Giuseppe, Saglio, Giovanni, Martinelli, Gianantonio, Rosti, Michele, Baccarani, G. I., M.

المصدر: Haematologica. 93:770-774

مصطلحات موضوعية: Oncology, medicine.medical_specialty, Time Factors, Phases of clinical research, Alpha interferon, IMATINIB, Disease-Free Survival, Piperazines, Cohort Studies, Chronic myeloid leukemia, Imatinib, Interferon-alpha, Long-term results, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Cytogenetics, Follow-Up Studies, Humans, Imatinib Mesylate, Immunologic Factors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Patient Compliance, Pyrimidines, Treatment Outcome, Hematology, Pegylated interferon, Internal medicine, medicine, Chronic, Interferon alfa, CHRONIC MYELOID LEUKEMIA, Leukemia, business.industry, Myeloid leukemia, medicine.disease, Imatinib mesylate, Immunology, BCR-ABL Positive, business, Myelogenous, medicine.drug, Chronic myelogenous leukemia

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b89ef090eb4fe1036e211b13f1f49aca
https://doi.org/10.3324/haematol.12265

2

Treatment decisions and outcome in very elderly patients with diffuse large B-Cell lymphoma

المؤلفون: Fabbri, Alberto, Cencini, Emanuele, Bocchia, Monica

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______1820::f1e19bf674ddaa2b5b4ff8143433c118
http://hdl.handle.net/11365/982457

3

دورية أكاديمية

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

View this record from ISI Web of Science

4

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis

المساهمون: S Luatti, F Castagnetti, G Marzocchi, C Baldazzi, G Gugliotta, I Iacobucci, G Specchia, L Zanatta, G Rege-Cambrin, M Mancini, E Abruzzese, A Zaccaria, M G Grimoldi, A Gozzetti, G Ameli, M A Capucci, G Palka, P Bernasconi, F Palandri, F Pane, G Saglio, G Martinelli, G Rosti, M Baccarani, N Testoni, on behalf of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML

مصطلحات موضوعية: Oncology, Myeloid, Male, Messenger, Biochemistry, Piperazines, Additional chromosomal abnormalities (ACA), European LeukemiaNet, hemic and lymphatic diseases, 80 and over, Medicine, Philadelphia Chromosome, Prospective Studies, Prospective cohort study, In Situ Hybridization, Fluorescence, In Situ Hybridization, Aged, 80 and over, Leukemia, Reverse Transcriptase Polymerase Chain Reaction, Hematology, Middle Aged, Prognosis, Survival Rate, medicine.anatomical_structure, Leukemia, Myeloid, Chronic-Phase, Benzamides, Cytogenetic Analysis, Imatinib Mesylate, Female, medicine.drug, Adult, medicine.medical_specialty, Adolescent, Immunology, Antineoplastic Agents, Philadelphia chromosome, Real-Time Polymerase Chain Reaction, IMATINIB, Fluorescence, Young Adult, Internal medicine, Humans, RNA, Messenger, Survival rate, Aged, Chromosome Aberrations, business.industry, Imatinib, Cell Biology, PHILADELPHIA-POSITIVE LEUKEMIAS, medicine.disease, Pyrimidines, eye diseases, stomatognathic diseases, Imatinib mesylate, RNA, Chronic-Phase, business, CHRONIC MYELOID LEUKEMIA (CML)

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0182962514a253864e1090aa081e9a6e
http://hdl.handle.net/11585/152802

5

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA WP on CML analysis

المساهمون: Marzocchi, G, Castagnetti, F, Luatti, S, Baldazzi, C, Stacchini, M, Gugliotta, G, Amabile, M, Specchia, G, Sessarego, M, Giussani, U, Valori, L, Discepoli, G, Montaldi, A, Santoro, A, Bonaldi, L, Giudici, G, Cianciulli, Am, Giacobbi, F, Palandri, F, Pane, Fabrizio, Saglio, G, Martinelli, G, Baccarani, M, Rosti, G, Testoni, N, Gruppo Italiano Malattie EMatologiche dell'Adulto Working Party on Chronic Myeloid, Leukemia, Marzocchi G., Castagnetti F., Luatti S., Baldazzi C., Stacchini M., Gugliotta G., Amabile M., Specchia G., Sessarego M., Giussani U., Valori L., Discepoli G., Montaldi A., Santoro A., Bonaldi L., Giudici G., Cianciulli A.M., Giacobbi F., Palandri F., Pane F., Saglio G., Martinelli G., Baccarani M., Rosti G., Testoni N.

مصطلحات موضوعية: Adult, Male, Oncology, medicine.medical_specialty, Adolescent, Immunology, Chromosomal translocation, Imatinib therapy, Biology, Biochemistry, Piperazines, Young Adult, European LeukemiaNet, diagnosis/drug therapy/genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, 80 and over, medicine, Humans, Philadelphia Chromosome, Chronic, Aged, Aged, 80 and over, Leukemia, medicine.diagnostic_test, Myeloid leukemia, Imatinib, Cell Biology, Hematology, Middle Aged, Prognosis, Survival Analysis, Pyrimidines, Imatinib mesylate, Adolescent, Adult, Aged, Aged, 80 and over, Cytogenetic Analysis, Female, Humans, Leukemia, Myelogenous, BCR-ABL Positive, diagnosis/drug therapy/genetics, Male, Middle Aged, Philadelphia Chromosome, Piperazines, therapeutic use, Prognosis, Pyrimidines, therapeutic use, Survival Analysis, Young Adult, therapeutic use, Benzamides, Cytogenetic Analysis, Female, Imatinib Mesylate, CHRONIC MYELOID LEUKEMIA (CML), Tyrosine kinase, Fluorescence in situ hybridization, medicine.drug

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49e4833acef18ea9e8497b2e55381b8d
http://hdl.handle.net/2318/91412

6

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

المساهمون: Castagnetti, F., Testoni, N., Luatti, S., Marzocchi, G., Mancini, M., Kerim, S., Giugliano, E., Albano, F., Cuneo, A., Abruzzese, E., Martino, B., Palandri, F., Amabile, M., Iacobucci, I., Alimena, G., Pane, Fabrizio, Martinelli, G., Saglio, G., Baccarani, M., Rosti, G., Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G, Castagnetti, F, Testoni, N, Luatti, S, Marzocchi, G, Mancini, M, Kerim, S, Giugliano, E, Albano, F, Cuneo, A, Abruzzese, E, Martino, B, Palandri, F, Amabile, M, Iacobucci, I, Alimena, G, Martinelli, G, Saglio, G, Baccarani, M

مصطلحات موضوعية: Oncology, poor-prognosis, Myeloid, Male, Cancer Research, Kaplan-Meier Estimate, Severity of Illness Index, Piperazines, European LeukemiaNet, fusion gene transcripts, Reference Values, hemic and lymphatic diseases, 80 and over, Prospective Studies, stem-cell transplantation, In Situ Hybridization, In Situ Hybridization, Fluorescence, Aged, 80 and over, Adolescent, Adult, Age Factors, Aged, Benzamides, Chromosomes, Human, Pair 9, Cytogenetic Analysis, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Imatinib Mesylate, Italy, Leukemia, Myeloid, Chronic-Phase, Logistic Models, Maximum Tolerated Dose, Middle Aged, Multivariate Analysis, Probability, Prognosis, Pyrimidines, Reverse Transcriptase Polymerase Chain Reaction, Risk Assessment, Statistics, Nonparametric, Survival Analysis, Treatment Outcome, Young Adult, Gene Deletion, Medicine (all), Leukemia, philadelphia-chromosome, Statistics, Myeloid leukemia, chronic myelogenous leukemia, medicine.anatomical_structure, abl tyrosine kinase, bcr expression, cytogenetic responses, minimal-residual-disease, patients receiving imatinib, Drug, medicine.drug, Human, Pair 9, medicine.medical_specialty, Derivative chromosome, Chromosomes, Fluorescence, Dose-Response Relationship, chronic myeloid leukemia, Internal medicine, medicine, Nonparametric, business.industry, Imatinib, medicine.disease, Imatinib mesylate, Immunology, Chronic-Phase, Bone marrow, business

وصف الملف: ELETTRONICO; STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::731620b3d4b33af3c2332aa3fd0d961c
http://hdl.handle.net/11588/371591

7

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

المساهمون: Castagnetti, F, Palandri, F, Amabile, M, Testoni, N, Luatti, S, Soverini, S, Iacobucci, I, Breccia, M, Rege Cambrin, G, Stagno, F, Specchia, G, Galieni, P, Iuliano, F, Pane, Fabrizio, Saglio, G, Alimena, G, Martinelli, G, Baccarani, M, Rosti, G.

المصدر: Blood. 113(15)

مصطلحات موضوعية: Oncology, Male, Biochemistry, Piperazines, Adult, Aged, Antineoplastic Agents, Benzamides, Disease-Free Survival, Female, Follow-Up Studies, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Middle Aged, Patient Compliance, Prospective Studies, Pyrimidines, Risk Factors, Treatment Outcome, Hematology, Cell Biology, Immunology, law.invention, Randomized controlled trial, law, hemic and lymphatic diseases, Chronic, Leukemia, Myeloid leukemia, Tolerability, Sokal Score, medicine.drug, medicine.medical_specialty, Adult, Aged, Antineoplastic Agents, administration /&/ dosage/adverse effects, Disease-Free Survival, Female, Follow-Up Studies, Humans, Leukemia, Myelogenous, BCR-ABL Positive, drug therapy/epidemiology, Male, Middle Aged, Patient Compliance, Piperazines, administration /&/ dosage/adverse effects, Prospective Studies, Pyrimidines, administration /&/ dosage/adverse effects, Risk Factors, Treatment Outcome, administration /&/ dosage/adverse effects, Internal medicine, medicine, business.industry, Imatinib, medicine.disease, drug therapy/epidemiology, Surgery, Clinical trial, Imatinib mesylate, business, Chronic myelogenous leukemia

وصف الملف: ELETTRONICO

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8544d0156519bfe1b31f42723dae22fc
https://pubmed.ncbi.nlm.nih.gov/19211938

8

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up

المساهمون: Francesca, Palandri, Fausto, Castagnetti, Giuliana, Alimena, Nicoletta, Testoni, Massimo, Breccia, Simona, Luatti, Giovanna Rege, Cambrin, Fabio, Stagno, Giorgina, Specchia, Bruno, Martino, Luciano, Levato, Serena, Merante, Anna Maria, Liberati, Pane, Fabrizio, Giuseppe, Saglio, Daniele, Alberti, Giovanni, Martinelli, Michele, Baccarani, Gianantonio, Rosti, Palandri, F, Castagnetti, F, Alimena, G, Testoni, N, Breccia, M, Luatti, S, Rege Cambrin, G, Stagno, F, Specchia, G, Martino, B, Levato, L, Merante, S, Liberati, Am, Saglio, G, Alberti, D, Martinelli, G, Baccarani, M, Rosti, G., Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G.

مصطلحات موضوعية: Oncology, Myeloid, Male, imatinib KeyWords Plus:CHRONIC MYELOGENOUS LEUKEMIA, ABL TYROSINE KINASE, PHILADELPHIA-CHROMOSOME, long-term results, Tyrosine-kinase inhibitor, Piperazines, accelerated phase, hemic and lymphatic diseases, 80 and over, Leukemia, INHIBITOR, Myeloid leukemia, Hematology, Middle Aged, chronic myeloid leukemia, imatinib, Survival Rate, Treatment Outcome, Benzamides, Cytogenetic Analysis, Imatinib Mesylate, Female, Complete Hematologic Response, medicine.drug, Adult, medicine.medical_specialty, medicine.drug_class, Author Keywords:chronic myeloid leukemia, CHRONIC GRANULOCYTIC LEUKEMIA, ACUTE LYMPHOBLASTIC-LEUKEMIA, STEM-CELL TRANSPLANTATION, INTERFERON-ALPHA, BLAST CRISIS, MESYLATE, Internal medicine, Multicenter trial, medicine, Humans, Survival rate, Aged, business.industry, Accelerated phase, Chronic myeloid leukemia, Imatinib, Long-term results, Aged, 80 and over, Follow-Up Studies, Leukemia, Myeloid, Accelerated Phase, Pyrimidines, Original Articles, medicine.disease, Surgery, Imatinib mesylate, business, Chronic myelogenous leukemia

وصف الملف: STAMPA; ELETTRONICO

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca59aad2046b936bf717a921eb03e02e
http://hdl.handle.net/11573/32508

9

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML

المساهمون: Francesca, Palandri, Ilaria, Iacobucci, Giovanni, Martinelli, Marilina, Amabile, Angela, Poerio, Nicoletta, Testoni, Simona, Soverini, Fausto, Castagnetti, Antonio De, Vivo, Massimo, Breccia, Giorgina, Specchia, Elisabetta, Abruzzese, Bruno, Martino, Daniela, Cilloni, Giuseppe, Saglio, Pane, Fabrizio, Anna Marina, Liberati, Gianantonio, Rosti, Michele, Baccarani, G. I., M., Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E, Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G, Baccarani M, GIMEMA Working Party on CML.

مصطلحات موضوعية: Male, Cancer Research, Time Factors, Messenger, Drug Resistance, Fusion Proteins, bcr-abl, Gastroenterology, Piperazines, 80 and over, FAILURE, Prospective Studies, RNA, Neoplasm, Chronic, Prospective cohort study, Proto-Oncogene Proteins c-abl, BCR-ABL, MOLECULAR RESPONSE, Aged, 80 and over, Leukemia, CHRONIC MYELOGENOUS LEUKEMIA, Myeloid leukemia, Middle Aged, Prognosis, Survival Rate, Treatment Outcome, Oncology, Cohort, Benzamides, Proto-Oncogene Proteins c-bcr, Imatinib Mesylate, Female, medicine.drug, MESYLATE THERAPY, FOLLOW-UP, INTERFERON-ALPHA, SURVIVAL BENEFIT, BLAST CRISIS, MANAGEMENT, Adult, medicine.medical_specialty, Alpha interferon, Antineoplastic Agents, Aged, Drug Resistance, Neoplasm, Humans, Interferon-alpha, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Pyrimidines, RNA, Messenger, COMPLETE CYTOGENETIC RESPONDERS (CCR), Internal medicine, medicine, IMATINIB MESYLATE (IM), Survival rate, business.industry, LATE CHRONIC PHASE (LCP), Fusion Proteins, Imatinib, medicine.disease, Surgery, Imatinib mesylate, Neoplasm, RNA, BCR-ABL Positive, business, Chronic myelogenous leukemia, Myelogenous

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e1101b4618cdc93fb0b9e3368aed16
http://hdl.handle.net/11588/342491

10

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia

المساهمون: Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M., Soverini, S, Martinelli, G, Rosti, G, Bassi, S, Amabile, M, Poerio, A, Giannini, B, Trabacchi, E, Castagnetti, F, Testoni, N, Luatti, S, DE VIVO, A, Cilloni, D, Izzo, Barbara, Fava, M, Abruzzese, E, Alberti, D, Pane, Fabrizio, Saglio, G, Baccarani, M.

مصطلحات موضوعية: Myeloid, Male, Oncology, Cancer Research, DNA Mutational Analysis, Drug Resistance, TYROSINE KINASE, Piperazines, hemic and lymphatic diseases, BCR-ABL, Chromatography, High Pressure Liquid, Chromatography, Leukemia, ABL, CLINICAL RESISTANCE, Reverse Transcriptase Polymerase Chain Reaction, Statistics, CHRONIC MYELOGENOUS LEUKEMIA, Myeloid leukemia, Middle Aged, Prognosis, medicine.anatomical_structure, High Pressure Liquid, Benzamides, Cytogenetic Analysis, Leukemia, Myeloid, Chronic-Phase, Disease Progression, Imatinib Mesylate, Female, medicine.drug, Adult, medicine.medical_specialty, POSITIVE CELLS, Antineoplastic Agents, Genes, abl, Statistics, Nonparametric, Internal medicine, medicine, Humans, Point Mutation, Nonparametric, PERFORMANCE LIQUID-CHROMATOGRAPHY, ACUTE LYMPHOBLASTIC-LEUKEMIA, KINASE INHIBITOR BMS-354825, I DOSE-ESCALATION, DOMAIN MUTATIONS, Aged, Chi-Square Distribution, business.industry, Point mutation, abl, Imatinib, medicine.disease, Survival Analysis, Pyrimidines, Imatinib mesylate, Genes, Drug Resistance, Neoplasm, Immunology, Neoplasm, ABL MUTATIONS, Chronic-Phase, Bone marrow, Blast Crisis, business

وصف الملف: STAMPA

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b3b1e12a46aa55946e937dd9649158d
http://hdl.handle.net/2318/1454

تنقيح النتائج